Kyxata Injection
Product Images NDC 83831-142

Product Visual Gallery

This gallery contains 9 technical images submitted to the FDA as part of the official labeling for Kyxata (NDC 83831-142). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Avyxa Pharma, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Image (0674943f 7498 497e B788 A9f12e62383d 112 1)

FDA Label Image

Image (1960f327 Faf2 49b2 B6ad Df9340c0ebc3 01)

FDA Label Image

Kyxata (carboplatin) Injection, 20 mg/2 mL (10 mg/ml) -vial Label (1960f327 Faf2 49b2 B6ad Df9340c0ebc3 02)

FDA Label Image

Kyxata (carboplatin) Injection, 20 mg/2 mL (10 mg/ml) -carton Label (1960f327 Faf2 49b2 B6ad Df9340c0ebc3 03)

This text excerpt contains information about a medication called KYXATA, specifically a 2 mL multiple-dose vial containing 20 mg of Carboplatin, USP, and Water for Injection. It provides details regarding dosage, storage instructions, expiration date, and the manufacturer's information. The medication is intended for intravenous use and is labeled as a hazardous drug. It is important to follow the prescribing information and store the vial appropriately to maintain its efficacy.*

FDA Label Image

Kyxata (carboplatin) Injection, 80 mg/8 mL (10 mg/ml) -vial Label (1960f327 Faf2 49b2 B6ad Df9340c0ebc3 04)

FDA Label Image

Kyxata (carboplatin) Injection, 80 mg/8 mL (10 mg/ml) -carton Label (1960f327 Faf2 49b2 B6ad Df9340c0ebc3 05)

This is a product label for a carboplatin injection solution. The medication is used intravenously and comes in an 80 mg/8 mL (10 mg/mL) concentration. It is a hazardous drug and should be stored between 20°C and 25°C (68°F to 77°F), with excursions permitted from 15°C to 30°C (59°F to 86°F). The solution should be protected from light and partially used vials stored in their original carton. The vials do not contain any preservatives. It is recommended to discard the solution after 28 days of first use. The product is manufactured for Aupra Pharma, LLC, in New Jersey, USA.*

FDA Label Image

Kyxata (carboplatin) Injection, 500 mg/50 mL (10 mg/ml) -vial Label (1960f327 Faf2 49b2 B6ad Df9340c0ebc3 06)

FDA Label Image

Kyxata (carboplatin) Injectionn, 500 mg/50 mL (10 mg/ml) -carton Label (1960f327 Faf2 49b2 B6ad Df9340c0ebc3 07)

This is a product description for KYXATA™ (CARBOplatin) Injection, containing 500 mg of Garboplatin per 50 mL vial for Intravenous Use. The medication is classified as a Hazardous Drug and is supplied as a Sterile Multiple-dose Vial. The vial does not contain any preservatives. The recommended storage temperature is between 20°C to 25°C (68°F to 77°F), with excursions permitted between 15°C to 30°C (59°F to 86°F). Once opened, the partially used vial should be stored in the original carton at the same temperature and discarded after 28 days. The product is manufactured for Avxa Pharma, LLC in the USA and made in Switzerland.*

FDA Label Image

Image (1960f327 Faf2 49b2 B6ad Df9340c0ebc3 178 2)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.